Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Clinical Trial on the Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients With Homologous Recombination Deficiency

Next Previous
Search
Trial Profile

Phase II Clinical Trial on the Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients With Homologous Recombination Deficiency

Status: Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 05 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carboplatin (Primary) ; Eribulin (Primary) ; Veliparib (Primary)
  • Indications Breast cancer; Ovarian cancer
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 09 Oct 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
  • 17 Aug 2017 Planned initiation date changed from 31 Jul 2017 to 30 Sep 2017.
  • 16 Jun 2017 Planned initiation date changed from 31 May 2017 to 31 Jul 2017.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top